Fezolinetant Shows Real-World Benefits for Menopausal Symptoms: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Expands Use of GSK's Gepotidacin as Oral Treatment for Uncomplicated Urogenital Gonorrhea
Gepotidacin becomes the first new oral antibiotic for gonorrhea in over 30 years, offering hope for effective treatment options.
Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial
Both doses of the GLP-1, GIP, glucagon triple agonist (9- and 12-mg) met all primary and key secondary endpoints and reduced CV risk factors as well, Eli Lilly said.
Two Global Phase 3 Trials Confirm Efficacy of Rocatinlimab for People With Moderate-to-Severe Atopic Dermatitis
Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.
WHO Safety Panel Updates Evidence Review, Confirms Vaccines Do Not Cause Autism
WHO experts weighed decades of high-quality studies against flawed analyses, finding consistent evidence that current vaccines pose no autism-related risk.
FDA Clears First At-Home Brain-Stimulation Device for Major Depression
Flow Therapeutics announced approval of its Flow-100 tDCS therapy for depression, which could expand access to non-pharmacologic care and will be available in the US in H2 2026.
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching: Daily Dose
Agitation in Alzheimer Disease: Proactive Assessment and Caregivers' Roles with Carolyn Clevenger, GNP
Clevenger speaks to primary care clinicians, emphasizing 3 priorities: engage family as partners, ask about agitation, and recognize its danger to patient and caregiver.
Q&A: Real-World Performance of Intranasal Epinephrine (neffy) in Anaphylaxis Management
Intranasal epinephrine emerges as a safe, effective alternative for anaphylaxis treatment, offering ease of use and promising real-world results.
Weekly Dose Podcast: New AD Blood Test, Elinzanetant’s Sleep Effects, Lung Cancer Screening Success, Menopause Symptom Burden, and VMS Treatment Approval
Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.
Genetic Evidence Supports a Causal Link Between Psoriasis and Depression
Genetic predisposition to psoriasis appears to raise depression risk, offering insights into shared inflammatory mechanisms and implications for screening.
Routine Alcohol Screening Scores Linked to Mortality Risk in Primary Care Patients
A cohort study of 531 851 primary care patients found routine AUDIT-C alcohol screening scores predict 8-year all-cause mortality, with strongest effects in younger adults.
FDA Opens Safety Review of RSV Monoclonal Antibodies Used in Infants
The inquiry follows internal requests for closer review of trial findings and real-world evidence; regulators have not yet indicated any planned actions.
New AHS Emergency Department Migraine Guideline Elevates Prochlorperazine and Nerve Blocks, Advises Again Against Opioids
The revised AHS guideline recommends treatments that offer the strongest benefit at ED discharge and identifies options with limited or no supporting evidence.
FDA Approves Elinzanetant for Moderate-to-Severe Vasomotor Symptoms of Menopause: Daily Dose
New 5-Minute Test Accurately Distinguishes HIV Infection from Vaccine-Induced False Positives
A new rapid HIV test accurately differentiates vaccine-induced false positives from active HIV-1 infection, potentially improving diagnostics and vaccine trials.
Perimenopause Misdiagnosis Remains Widespread as Clinicians Miss Hormonal Transition Explains Bruce Dorr, MD, URPS, IFM-CP
Ob/gyn Dorr outlines how short clinical visits and symptom overlap cause many women to receive an antidepressant Rx instead of perimenopause care.
Dupilumab and Other Monoclonals Rank Highly for Moderate-to-Severe Atopic Dermatitis, Network Meta-Analysis Shows
A new meta-analysis reveals monoclonal antibodies, including dupilumab, outperform placebo in treating moderate-to-severe atopic dermatitis.
Kallyope's Oral TRPM8 Antagonist Advances Toward Registrational Studies for Acute Migraine Treatment
Kallyope reported favorable phase 2b data in acute migraine for elismetrep, a novel ion channel protein, highlighting competitive efficacy and good tolerability.
PreP Dispensing Barriers Linked to Higher HIV Incidence: US Claims Analysis
Formulary restrictions and prior authorization requirements block access to newer PrEP options, while cost sharing over $50 cuts dispensing odds by 93%.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "FDA Expands Use of GSK's Gepotidacin as Oral Treatment for Uncomplicated Urogenital Gonorrhea")
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Two Global Phase 3 Trials Confirm Efficacy of Rocatinlimab for People With Moderate-to-Severe Atopic Dermatitis / image credit: MJH life sciences")
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "New 5-Minute Test Accurately Distinguishes HIV Infection from Vaccine-Induced False Positives")
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Dupilumab and Other Monoclonals Rank Highly for Moderate-to-Severe Atopic Dermatitis, Network Meta-Analysis Shows / Image credit: ©aamylya/AdobeStock")
